文献速递神经创伤神经重症

重型颅脑创伤死亡患者血清sCD40L水平持续升高

Nonsurviving Patients with Severe Traumatic Brain Injury Have Maintained High Serum sCD40L Levels.
PubMed 文献 · World Neurosurg · 2019-03-27

这项多中心研究纳入重型颅脑创伤(GCS<9)患者,检测伤后第1、4、8天血清sCD40L浓度,比较存活与死亡患者并评估30天死亡预测能力。死亡患者(n=34)第1、4、8天sCD40L均高于存活患者(n=90);第1、4、8天预测30天死亡的曲线下面积分别为82%、72%、83%。

要点

  • 死亡组第1、4、8天血清sCD40L水平均高于存活组。
  • 第1、4、8天sCD40L预测30天死亡的AUC分别为82%、72%、83%。
  • 伤后第一周血清sCD40L或可作为死亡预测生物标志物。

核心结论

  • 重型颅脑创伤后第一周死亡患者血清sCD40L水平高于存活患者,且第一周sCD40L水平可作为死亡预测生物标志物。

研究设计与样本

  • 多中心研究,纳入格拉斯哥昏迷评分<9且非颅内部位损伤严重度评分<9的重型颅脑创伤患者,检测伤后第1、4、8天血清sCD40L浓度,并行受试者工作特征分析评估30天死亡预测能力。

主要发现

  • 死亡组(n=34)伤后第1天sCD40L水平高于存活组(n=90),P<0.001。
  • 死亡组伤后第4天sCD40L水平高于存活组,P=0.004。
  • 死亡组伤后第8天sCD40L水平高于存活组,P<0.001。
  • 伤后第1天sCD40L预测30天死亡的曲线下面积为82%(P<0.001)。
  • 伤后第4天sCD40L预测30天死亡的曲线下面积为72%(P=0.01),第8天为83%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soluble cluster of differentiation 40 ligand (sCD40L) is a member of the tumor necrosis factor family with proinflamatory and procoagulant effects. A previous study found higher serum sCD40L levels at day 1 of traumatic brain injury (TBI) in nonsurviving than surviving patients. Thus the objective of this study was to compare serum sCD40L levels during the first week of a severe TBI between surviving and nonsurviving patients and to determine whether it could be used as a mortality predictor biomarker. METHODS: In this multicenter study severe TBI patients (with Glasgow Coma Scale score <9) with an Injury Severity Score in noncranial item <9 were included. Serum sCD40L concentrations at days 1, 4, and 8 of TBI were determined. We performed receiver operating characteristic analyses to determine the capacity of 30-day TBI mortality prediction by serum sCD40L levels at days 1, 4, and 8 of TBI. RESULTS: We found that nonsurviving (n = 34) patients in comparison with surviving (n = 90) patients had higher sCD40L levels on days 1 (P < 0.001), 4 (P = 0.004), and 8 (P < 0.001) of TBI. We also found that the areas under curve of serum sCD40L concentrations at days 1, 4, and 8 of TBI to 30-day mortality prediction were 82% (P < 0.001), 72% (P = 0.01) and 83% (P < 0.001), respectively. CONCLUSIONS: The existence of higher serum sCD40L levels in nonsurviving than surviving patients during the first week of TBI and fact that serum sCD40L levels during the first week of TBI can be used as a mortality predictor biomarker are the new findings of our study.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lorente L, Martín MM, González-Rivero AF, et al. Nonsurviving Patients with Severe Traumatic Brain Injury Have Maintained High Serum sCD40L Levels. World Neurosurg. 2019. PMID: 30926559. doi:10.1016/j.wneu.2019.03.179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。